LNTH News and Press, Lantheus Holdings Inc. From 06/09/22

Recent financial performance reported by Bausch + Lomb has been encouraging from a sales perspective. However, the company's bottom line is facing continued difficulties. But given how cheap shares of the business are today, it does seem to offer some upside potential even if risk...

NORTH BILLERICA, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The markets aren’t incredibly predictable right now and the typical hot stocks aren’t establishing leadership yet. But that doesn’t mean there aren’t stocks that are worth buying. The hot stock...

NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...

NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17, beginning at 9:00 a.m. EDT. Members of Lantheus’ management team will provi...

NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Lantheus (NASDAQ:LNTH) said on Friday it had begun dosing the first patient in a Phase 2 trial evaluating its imaging agent used to assess PD-L1 expression in cancer cells, NM-01. The trial, dubbed Pelican, is a single-arm trial in non-small cell lung cancer patients. The main ...

NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...

NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...